NRX — Nurexone Biologic Income Statement
0.000.00%
Last trade - 00:00- CA$70.09m
- CA$68.50m
Annual income statement for Nurexone Biologic, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.062 | 0.132 | 7.62 | 3.66 | 5.01 |
| Operating Profit | -0.062 | -0.132 | -7.62 | -3.66 | -5.01 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.021 | -0.132 | -8.17 | -3.64 | -5.04 |
| Net Income After Taxes | -0.021 | -0.132 | -8.17 | -3.64 | -5.04 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.021 | -0.132 | -8.17 | -3.64 | -5.04 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.021 | -0.132 | -8.17 | -3.64 | -5.04 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.008 | -0.052 | -0.161 | -0.081 | -0.077 |